Melanoma trials in Portugal

In Portugal 7 Also abroad 579

7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Where
Funchal, Lisbon
Age
18 years and over
People
632 worldwide
Run by
mAbxience Research S.L.
See details and how to joinNCT07221734
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Lisbon, Porto
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Where
Lisbon, Porto
Age
18 years and over
People
160 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06961006
Phase 1/2Taking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
Porto
Age
6 months to 17 years
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
Phase 3Taking people
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
Where
Funchal, Lisbon
Age
18 years and over
People
119 worldwide
Run by
Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00
Phase 3Taking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Coimbra, Lisbon
Age
18 years and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314